Evaluation of serum cholesterol reduction and xanthine oxidase inhibition in the treatment of atherosclerosis.
D000328:Adult; D000368:Aged; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D005260:Female; D005492:Folic Acid / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008892:Milk / Q000009:adverse effects; D008894:Milk Proteins / Q000378:metabolism; D014527:Uric Acid / Q000097:blood; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism
D000924:Anticholesteremic Agents; D008894:Milk Proteins; D014527:Uric Acid; D005492:Folic Acid; D002784:Cholesterol; D014969:Xanthine Oxidase